202 related articles for article (PubMed ID: 23686000)
1. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
Schnichels S; Hagemann U; Januschowski K; Hofmann J; Bartz-Schmidt KU; Szurman P; Spitzer MS; Aisenbrey S
Br J Ophthalmol; 2013 Jul; 97(7):917-23. PubMed ID: 23686000
[TBL] [Abstract][Full Text] [Related]
2. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
[TBL] [Abstract][Full Text] [Related]
3. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis.
Klettner A; Tahmaz N; Dithmer M; Richert E; Roider J
Br J Ophthalmol; 2014 Oct; 98(10):1448-52. PubMed ID: 25034050
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
5. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
Sheu SJ; Chao YM; Liu NC; Chan JY
Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
[TBL] [Abstract][Full Text] [Related]
7. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
Malik D; Tarek M; Caceres del Carpio J; Ramirez C; Boyer D; Kenney MC; Kuppermann BD
Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i11-16. PubMed ID: 24836865
[TBL] [Abstract][Full Text] [Related]
8. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
[TBL] [Abstract][Full Text] [Related]
9. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
10. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S
Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiological toxicity testing of VEGF Trap-Eye in an isolated perfused vertebrate retina organ culture model.
Januschowski K; Schnichels S; Hagemann U; Koch V; Hofmann J; Spitzer MS; Bartz-Schmidt KU; Szurman P; Lüke M; Aisenbrey S
Acta Ophthalmol; 2014 Jun; 92(4):e305-11. PubMed ID: 24206925
[TBL] [Abstract][Full Text] [Related]
12. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage.
Thaler S; Fiedorowicz M; Choragiewicz TJ; Bolz S; Tura A; Henke-Fahle S; Yoeruek E; Zrenner E; Bartz-Schmidt KU; Ziemssen F; Schuettauf F
Acta Ophthalmol; 2010 Aug; 88(5):e170-6. PubMed ID: 20491691
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
[TBL] [Abstract][Full Text] [Related]
14. The effects of aflibercept on the viability and metabolism of ocular cells in vitro.
Ammar DA; Mandava N; Kahook MY
Retina; 2013 May; 33(5):1056-61. PubMed ID: 23266881
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells.
Brar VS; Sharma RK; Murthy RK; Chalam KV
J Ocul Pharmacol Ther; 2009 Dec; 25(6):507-11. PubMed ID: 20028259
[TBL] [Abstract][Full Text] [Related]
16. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
Chae JB; Rho CR; Shin JA; Lyu J; Kang S
Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
Klettner A; Recber M; Roider J
Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells.
Spitzer MS; Wallenfels-Thilo B; Sierra A; Yoeruek E; Peters S; Henke-Fahle S; Bartz-Schmidt KU; Szurman P;
Br J Ophthalmol; 2006 Oct; 90(10):1316-21. PubMed ID: 16723358
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line.
Sharma RK; Chalam KV
Acta Ophthalmol; 2009 Sep; 87(6):618-22. PubMed ID: 19563375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]